Neogenix Oncology, Inc. (Neogenix) announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company's monoclonal antibody for colorectal and pancreatic cancer. Invented and developed by Neogenix Oncology, this antibody has shown anti-tumor effects for both pancreatic and colorectal tumors in both in vitro and animal studies and may have both therapeutic and diagnostic applications. This patent covers the third distinct monoclonal antibody held by Neogenix.
"This patent is another major step for Neogenix to move forward in our research for the diagnosis and treatment of a broad range of cancers. We believe that 16C3 has the potential to become an important addition to Neogenix's new diagnostic and therapeutic tools in the fight against colorectal and pancreatic cancer. The antibody may have activity in other tumors as well, which the company will explore as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody," said Neogenix President and Chief Executive Officer, Philip M. Arlen, MD.
The USPTO has previously granted patents for Neogenix Oncology's lead monoclonal antibody NPC-1C (ensituximab) as well as its monoclonal antibody, 31.1.
Breakthrough imaging method enhances precision in prostate cancer treatment